PMID- 33995594
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220423
IS  - 1758-8340 (Print)
IS  - 1758-8359 (Electronic)
IS  - 1758-8340 (Linking)
VI  - 13
DP  - 2021
TI  - Antacid exposure and immunotherapy outcomes among patients with advanced 
      hepatocellular carcinoma.
PG  - 17588359211010937
LID - 10.1177/17588359211010937 [doi]
LID - 17588359211010937
AB  - BACKGROUND: Antibiotic exposure has been associated with worse outcomes with 
      immune checkpoint inhibitors (ICIs) in cancer patients, likely due to disruption 
      of the gut microbiome. Other commonly prescribed medications, such as proton pump 
      inhibitors (PPIs) and histamine-2-receptor antagonists (H2RAs), are also known to 
      disrupt the microbiome, but data on their association with ICI outcomes are 
      conflicting. METHODS: We conducted a retrospective, multicenter, international 
      cohort study including 314 hepatocellular carcinoma (HCC) patients treated with 
      ICIs from 2017 to 2019 to assess the association between PPI or H2RA exposure (up 
      to 30 days before ICI) and overall survival. Secondary outcomes included overall 
      response rate (ORR) and development of any treatment-related adverse events 
      (AEs). RESULTS: Baseline PPI/H2RA exposure was not associated with overall 
      survival in univariable (HR 1.01, 95% CI 0.75-1.35) or multivariable analysis (HR 
      0.98, 95% CI 0.71-1.36). Baseline PPI/H2RA exposure was not associated with 
      either ORR (OR 1.32, 95% CI 0.66-2.65) or AEs (OR 1.07, 95% CI 0.54-2.12) in 
      multivariable analysis. CONCLUSIONS: Our results suggest that exposure to 
      PPI/H2RA prior to ICIs does not adversely affect outcomes in HCC patients.
CI  - (c) The Author(s), 2021.
FAU - Jun, Tomi
AU  - Jun T
AUID- ORCID: 0000-0002-2120-1704
AD  - Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School 
      of Medicine at Mount Sinai, New York, NY, USA.
FAU - Ozbek, Umut
AU  - Ozbek U
AD  - Department of Population Health Science and Policy, Icahn School of Medicine at 
      Mount Sinai, New York, NY, USA.
FAU - Dharmapuri, Sirish
AU  - Dharmapuri S
AD  - Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School 
      of Medicine at Mount Sinai, New York, NY, USA.
FAU - Hardy-Abeloos, Camille
AU  - Hardy-Abeloos C
AD  - Icahn School of Medicine at Mount Sinai, New York, NY, USA.
FAU - Zhu, Huili
AU  - Zhu H
AD  - Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, 
      USA.
FAU - Lin, Jung-Yi
AU  - Lin JY
AD  - Department of Population Health Science and Policy, Icahn School of Medicine at 
      Mount Sinai, New York, NY, USA.
FAU - Personeni, Nicola
AU  - Personeni N
AD  - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, 
      Italy.
FAU - Pressiani, Tiziana
AU  - Pressiani T
AD  - Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas 
      Research Hospital, Rozzano, Milan, Italy.
FAU - Nishida, Naoshi
AU  - Nishida N
AD  - Department of Gastroenterology and Hepatology, Kindai University Faculty of 
      Medicine, Osaka-Sayama, Osaka, Japan.
FAU - Lee, Pei-Chang
AU  - Lee PC
AD  - Division of Gastroenterology and Hepatology, Department of Medicine, Taipei.
FAU - Lee, Chieh-Ju
AU  - Lee CJ
AD  - Division of Gastroenterology and Hepatology, Department of Medicine, Taipei.
FAU - Hildebrand, Hannah
AU  - Hildebrand H
AD  - Division of Medical Oncology, Department of Medicine, Kansas University Cancer 
      Center, Westwood, KS, USA.
FAU - Nimkar, Neil
AU  - Nimkar N
AD  - New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY, USA.
FAU - Paul, Sonal
AU  - Paul S
AD  - New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY, USA.
FAU - Fessas, Petros
AU  - Fessas P
AD  - Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, 
      London, UK.
FAU - Naeem, Muntaha
AU  - Naeem M
AD  - Department of Surgery and Cancer, Imperial College London, Hammersmith Hospital, 
      London, UK.
FAU - Bettinger, Dominik
AU  - Bettinger D
AD  - Department of Medicine II, Faculty of Medicine, Medical Center University of 
      Freiburg, University of Freiburg, Freiburg, Germany.
FAU - Khan, Uqba
AU  - Khan U
AD  - Division of Hematology and Oncology, Weill Cornell Medicine/New York Presbyterian 
      Hospital, New York, NY, USA.
FAU - Saeed, Anwaar
AU  - Saeed A
AD  - Division of Medical Oncology, Department of Medicine, Kansas University Cancer 
      Center, Westwood, KS, USA.
FAU - Huang, Yi-Hsiang
AU  - Huang YH
AD  - Division of Gastroenterology and Hepatology, Department of Medicine, Taipei.
FAU - Kudo, Masatoshi
AU  - Kudo M
AD  - Department of Gastroenterology and Hepatology, Kindai University Faculty of 
      Medicine, Osaka-Sayama, Osaka, Japan.
FAU - Rimassa, Lorenza
AU  - Rimassa L
AUID- ORCID: 0000-0001-9957-3615
AD  - Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, 
      Italy.
FAU - Marron, Thomas U
AU  - Marron TU
AD  - Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School 
      of Medicine at Mount Sinai, New York, NY, USA.
FAU - Pinato, David J
AU  - Pinato DJ
AD  - Imperial Centre for Translational and Experimental Medicine (ICTEM), 72 Du Cane 
      Road, White City, London, W12 0NN, UK Division of Oncology, Department of 
      Translational Medicine, Piemonte Orientale University, Novara, Italy.
FAU - Ang, Celina
AU  - Ang C
AD  - Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School 
      of Medicine at Mount Sinai, 1 Gustave Levy Place, Box 1079, New York, NY 10029, 
      USA.
LA  - eng
PT  - Journal Article
DEP - 20210428
PL  - England
TA  - Ther Adv Med Oncol
JT  - Therapeutic advances in medical oncology
JID - 101510808
PMC - PMC8107671
OTO - NOTNLM
OT  - antacid
OT  - hepatocellular carcinoma
OT  - immunotherapy
OT  - proton pump inhibitor
COIS- Conflict of interest statement: DJP received lecture fees from ViiV Healthcare 
      and Bayer Healthcare and travel expenses from BMS and Bayer Healthcare; 
      consulting fees for Mina Therapeutics, EISAI, Roche, and Astra Zeneca; received 
      research funding (to institution) from MSD and BMS. LR reports receiving 
      consulting fees from Amgen, ArQule, AstraZeneca, Basilea, Bayer, Celgene, Eisai, 
      Exelixis, Hengrui, Incyte, Ipsen, Lilly, MSD, Nerviano Medical Sciences, Roche, 
      Sanofi; lectures fees from AbbVie, Amgen, Eisai, Gilead, Incyte, Ipsen, Lilly, 
      Roche, Sanofi; travel fees from Ipsen; and institutional research funding from 
      Agios, ARMO BioSciences, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, 
      Ipsen, Lilly, MSD, Roche. NP reports receiving consulting fees from Amgen, Merck 
      Serono, Servier; lectures fees from AbbVie, Gilead, Lilly; travel fees from 
      Amgen, ArQule; and institutional research funding from Basilea, Merck Serono, 
      Servier. TP reports receiving institutional research funding from Lilly.
EDAT- 2021/05/18 06:00
MHDA- 2021/05/18 06:01
PMCR- 2021/04/28
CRDT- 2021/05/17 06:05
PHST- 2020/12/20 00:00 [received]
PHST- 2021/03/22 00:00 [accepted]
PHST- 2021/05/17 06:05 [entrez]
PHST- 2021/05/18 06:00 [pubmed]
PHST- 2021/05/18 06:01 [medline]
PHST- 2021/04/28 00:00 [pmc-release]
AID - 10.1177_17588359211010937 [pii]
AID - 10.1177/17588359211010937 [doi]
PST - epublish
SO  - Ther Adv Med Oncol. 2021 Apr 28;13:17588359211010937. doi: 
      10.1177/17588359211010937. eCollection 2021.